Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Carcinoma, Non-Small-Cell Lung 47Neoplasms 21Breast Neoplasms 19Triple Negative Breast Neoplasms 16Melanoma 15Urinary Bladder Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 13Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Solid Tumors 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Lymphoma 5Esophageal Neoplasms 5Stomach Neoplasms 4Lung Neoplasms 4Kidney Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Urologic Neoplasms 2Solid Tumor 2

Interventions

Rituximab 168Cyclophosphamide 142Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 68Filgrastim 64Etoposide 63Radiotherapy 55Vincristine 47Prednisone 45Mycophenolic Acid 44Melphalan 40Whole-Body Irradiation 39Cyclosporine 39Busulfan 39Tacrolimus 36Doxorubicin 34Cytarabine 33Lenalidomide 29Carmustine 28Antilymphocyte Serum 28Methotrexate 27Methylprednisolone 26Bortezomib 26Bendamustine Hydrochloride 26sargramostim 21ibritumomab tiuxetan 20obinutuzumab 19ibrutinib 18fludarabine 18Dexamethasone 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Lymphoma, Follicular × atezolizumab × Clear all
NCT03276468 2023-01-10

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

The Lymphoma Academic Research Organisation

Phase 2 Completed
136 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02631577 2022-04-13

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Hoffmann-La Roche

Phase 1/2 Completed
38 enrolled 20 charts
Lymphoid

Lymphoma, Follicular

NCT02596971 2021-05-24

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 1/2 Completed
91 enrolled 27 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡